Status:
ACTIVE_NOT_RECRUITING
REgiStry Of the NAtural History of recurreNt periCarditis in pEdiatric and Adult Patients
Lead Sponsor:
Kiniksa Pharmaceuticals International, plc
Collaborating Sponsors:
Kiniksa Pharmaceuticals (UK), Ltd.
Conditions:
Recurrent Pericarditis
Eligibility:
All Genders
7+ years
Brief Summary
The registry will focus on furthering the understanding of the natural history of recurrent pericarditis (RP), as well as document RP-related clinical, health-related quality of life (HRQoL), and econ...
Eligibility Criteria
Inclusion
- ACTIVE RP PATIENTS
- Select
- Physician-confirmed (or confirmation in medical records) diagnosis of RP defined as an initial, acute, episode and at least one pericarditis recurrence after the initial acute episode
- Experienced at least one pericarditis episode in the 3 years prior to inclusion
- Under the care of a physician for the treatment and management of RP
- Currently prescribed medication for RP
- Select
Exclusion
- Diagnosis of pericarditis secondary to tuberculosis (TB), cancer if not in full remission, post thoracic blunt trauma (e.g., motor-vehicle accidents), myocarditis, systemic autoimmune diseases, except SJIA and adult Still's disease, HIV
- Appears to have an impairment (e.g., cognitive, hearing, visual) or insufficient English or Spanish proficiency that could interfere with ability to complete patient-completed assessments
- Currently enrolled in a therapeutic investigational drug or device study
- INACTIVE RP PATIENTS
- Select Inclusion Criteria:
- Physician-confirmed (or confirmation in medical records) diagnosis of RP defined as an initial, acute, episode and at least one pericarditis recurrence after the initial, acute episode
- Patient had a last episode occurring at least 3 years and up to 5 years before registry inclusion
- Resolution of RP symptoms confirmed with no further RP treatment for 3 years prior to registry enrollment
- Select
Key Trial Info
Start Date :
March 16 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 1 2026
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT04687358
Start Date
March 16 2021
End Date
February 1 2026
Last Update
April 29 2025
Active Locations (29)
Enter a location and click search to find clinical trials sorted by distance.
1
Alaska Heart & Vascular Institute
Anchorage, Alaska, United States, 99508
2
Pima Heart and Vascular
Tucson, Arizona, United States, 85718
3
University of California San Diego Medical Center
La Jolla, California, United States, 92093
4
Cedars-Sinai Medical Center
Los Angeles, California, United States, 90048